ClinicalTrialStartPulse: all 1,000 record reports, page 1 of 5

Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 1 to 200: A.O.U. Città della Salute e della Scienza: Observational study in STEMI, NSTEMI (600 participants) to Fujian Medical University Union Hospital: Observational study in Acute Ischemic Stroke (2000 participants). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.

NONUS

• A.O.U. Città della Salute e della Scienza: Observational study in STEMI, NSTEMI (600 participants)
• Aarhus University Hospital: Observational study in Head and Neck Cancer (H&N), Thyroid Cancer (1500 participants)
• Abant Izzet Baysal University: Observational study in Body Hygiene Status in Bedbound Individuals (315 participants)
• Abant Izzet Baysal University: Observational study in Type 2 Diabetes (348 participants)
• AbbVie: Observational study in Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer (500 participants)
• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): Observational study in Hemorrhagic Stroke, Intracerebral, Subarachnoid Haemorrhage (SAH) (825 participants)
• Ache Laboratorios Farmaceuticos S.A.: Phase 3 study in Acute Pain (370 participants)
• Aeterna Medical Solutions SL: Observational study in Hypercholesterolemia, Cardiovascular Risk (100000 participants)
• Affidea Nu-med Center of Oncological DIagnostics and Therapy: Not applicable (device, behavioral) study in Solid Tumor (426 participants)
• Affidea Nu-med Center of Oncological DIagnostics and Therapy: Observational study in Cervical Cancer, Gynecologic Cancer (500 participants)
• Affiliated Hospital of Nantong University: Observational study in Stroke, Ischemic Stroke (5000 participants)
• Agenzia di Tutela della Salute della Città Metropolitana di Milano: Not applicable (device, behavioral) study in Well Being, Drug Addiction (3927 participants)
• Ahn-Gook Pharmaceuticals Co.,Ltd: Observational study in Hypertension (HTN), Hypertension (4528 participants)
• Ain Shams University: Phase 3 study in Surgical Site Infection (SSI), Spine Diseases (416 participants)
• AlFayhaa General Hospital: Observational study in ENT Outpatient Conditions (600 participants)
• All India Institute of Medical Sciences: Phase 3 study in Acute Ischemic Stroke (440 participants)
• Alliance for Clinical Trials in Oncology: Phase 3 study in Multiple Myeloma (MM) (920 participants)
• Alliance for International Medical Action: Observational study completed, 1100 enrolled (Lassa Fever, Lassa Virus Infection)
• Ambulanzpartner Soziotechnologie APST GmbH: Observational study in ALS (Amyotrophic Lateral Sclerosis), SMA - Spinal Muscular Atrophy (2000 participants)
• Amgen: Phase 3 study in Diabetes Mellitus, Type 2 (1300 participants)
• Andijan State Medical Institute: Observational study in Psychometric Validation of Men's Health Questionnaires (400 participants)
• Ankara City Hospital Bilkent: Observational study completed, 700 enrolled (Difficult Intubation, Holmium Laser Enucleation of the Prostate)
• Ankara University: Not applicable (device, behavioral) study in Postoperative Pain After Endodontic Treatment, Oral Health-Related Quality of Life (324 participants)
• Ankara University: Observational study in Peri-implantitis, Alveolar Bone Loss (784 participants)
• Army Medical University, China: Not applicable (device, behavioral) study in Children's Dental Fear (400 participants)
• Arsène Brunelle Sandie: Not applicable (device, behavioral) study completed, 17188 enrolled (Papillomavirus Infections, Uterine Cervical Neoplasms)
• Assaf-Harofeh Medical Center: Observational study in Traumatic Brain Injury, Post-Concussion Syndrome (1000 participants)
• Assistance Publique - Hôpitaux de Paris: Not applicable (device, behavioral) study closed enrollment, 529 enrolled (Renal Transplantation)
• Assistance Publique - Hôpitaux de Paris: Not applicable (device, behavioral) study in Heart Transplantation (352 participants)
• Assistance Publique - Hôpitaux de Paris: Not applicable (device, behavioral) study started recruiting, 528 planned (Parkinson Disease, Impulse Control Disorder)
• Assistance Publique - Hôpitaux de Paris: Observational study in ECMO Cannula Infection, Extracorporel Membrane Oxygenation Complication (500 participants)
• Assistance Publique - Hôpitaux de Paris: Observational study in Ehlers-Danlos Syndromes (EDS) (3500 participants)
• Assistance Publique - Hôpitaux de Paris: Observational study in Neuromuscular Diseases (NMD), Pneumothorax (31202 participants)
• Assistance Publique - Hôpitaux de Paris: Observational study in Noninfectious Uveitis (500 participants)
• Assistance Publique - Hôpitaux de Paris: Observational study in Vaccination Coverage Among Pregnant Women (1605 participants)
• Assistance Publique - Hôpitaux de Paris: Phase 2 study in Acute Appendicitis (560 participants)
• Assiut University: Observational study in Acute STEMI, PPCI (450 participants)
• Assiut University: Observational study in Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms (500 participants)
• Assiut University: Observational study in Lifestyle Behaviors (579 participants)
• Astana Medical University: Observational study in Small Bowel Adhesion, Obstruction Bowel (1500 participants)
• Astellas Pharma Europe Ltd.: Observational study in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (1000 participants)
• AstraZeneca: Observational study closed enrollment, 367 enrolled (Atypical Hemolytic Uremic Syndrome(aHUS))
• AstraZeneca: Observational study closed enrollment, 625 enrolled (Breast Cancer)
• AstraZeneca: Observational study closed enrollment, 752 enrolled (Ovarian Cancer)
• AstraZeneca: Observational study completed, 1368 enrolled (COPD)
• AstraZeneca: Observational study in Lymphoma, B-Cell (532 participants)
• AstraZeneca: Observational study in Neurofibromatosis Type 1 (NF1) (800 participants)
• AstraZeneca: Phase 3 study in Large B-cell Lymphoma (1200 participants)
• AstraZeneca: Phase 4 study closed enrollment, 731 enrolled (Chronic Kidney Disease)
• Austrian Breast & Colorectal Cancer Study Group: Observational study started recruiting, 600 planned (Rectal Cancer, Adenocarcinoma of Rectum)
• AVEO Pharmaceuticals, Inc.: Phase 3 study in Cachexia; Cancer, Cachexia (950 participants)
• Azienda Ospedaliero-Universitaria Careggi: Observational study in Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension (5000 participants)
• Balikesir University: Not applicable (device, behavioral) study in Healthy Eating, Nutrition Literacy (334 participants)
• Başakşehir Çam & Sakura City Hospital: Observational study completed, 330 enrolled (Nasal Septum, Irregular, Nasal Septal Defect)
• Başakşehir Çam & Sakura City Hospital: Observational study in Multiple Myeloma (420 participants)
• Basavatarakam Indo American Cancer Hospital & Research Institute: Not applicable (device, behavioral) study in Rectal Cancer Patients, Rectal Cancer Surgery (610 participants)
• Bayer: Observational study closed enrollment, 1081 enrolled (Renal Anemia)
• Bayer: Observational study closed enrollment, 529 enrolled (Chronic Kidney Disease, Type 2 Diabetes Mellitus)
• Bayer: Observational study completed, 604 enrolled (Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure)
• Beijing Anzhen Hospital: Not applicable (device, behavioral) study in Atrial Fibrillation (AF), Ablation Treatment (700 participants)
• Beijing BeneWill Technology Development Co., Ltd: Phase 3 study in Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD) (25000 participants)
• Beijing Chao Yang Hospital: Observational study in Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis) (2800 participants)
• Beijing Chao Yang Hospital: Observational study in Pulmonary Nodules, Early Detection of Cancer (1050 participants)
• Beijing Chao Yang Hospital: Observational study in Sedation, Analgesia Assessment (2000 participants)
• Beijing Ditan Hospital: Phase 3 study in Neurosyphilis (778 participants)
• Beijing InnoCare Pharma Tech Co., Ltd.: Phase 2 study in Advanced Solid Tumor (348 participants)
• Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd: Phase 2 study in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (384 participants)
• Beijing Suncadia Pharmaceuticals Co., Ltd: Phase 3 study closed enrollment, 367 enrolled (Hypertriglyceridemia)
• Beijing Tiantan Hospital: Observational study in Moyamoya Disease, Moyamoya Syndrome (3000 participants)
• Beijing Tiantan Hospital: Observational study in Unruptured Intracranial Aneurysm, Intracranial Aneurysm Rupture (2000 participants)
• Beijing Tsinghua Chang Gung Hospital: Not applicable (device, behavioral) study in Biliary Tract Cancer (BTC) (10000 participants)
• Beijing Tsinghua Chang Gung Hospital: Observational study in Chronic Heart Failure (918 participants)
• Beijing Tsinghua Chang Gung Hospital: Observational study in Congenital Biliary Dilatation (4341 participants)
• Beta Bionics, Inc.: Not applicable (device, behavioral) study in Diabetes (Insulin-requiring, Type 1 or Type 2) (400 participants)
• BetaPlus Center for Reproductive Medicine: Observational study in IVF Outcomes, Prediction Models (2200 participants)
• Bioaraba Health Research Institute: Not applicable (device, behavioral) study completed, 390 enrolled (Alcoholic Hepatitis)
• Biodesix, Inc.: Observational study in Indeterminate Pulmonary Nodule (1000 participants)
• Biohaven Therapeutics Ltd.: Phase 3 study in Graves' Disease (356 participants)
• bioLytical Laboratories: Not applicable (device, behavioral) study in HCV Infection (1660 participants)
• bioLytical Laboratories: Not applicable (device, behavioral) study in HCV Infection (388 participants)
• Bionime Corporation: Not applicable (device, behavioral) study in Diabetes (DM) (324 participants)
• Boston Scientific Corporation: Observational study closed enrollment, 501 enrolled (Paroxysmal AF)
• Boston Scientific Corporation: Observational study closed enrollment, 524 enrolled (Atrial Fibrillation (AF))
• Boston Scientific Corporation: Observational study closed enrollment, 550 enrolled (Atrial Fibrillation, Pulsed Field Ablation)
• BRAC University: Not applicable (device, behavioral) study in Heat Cramps, Heat Rash (2875 participants)
• Brigham and Women's Hospital: Observational study closed enrollment, 200000 enrolled (Herpes Zoster (HZ))
• BrightGene Bio-Medical Technology Co., Ltd.: Phase 3 study started recruiting, 372 planned (Type 2 Diabetes (T2DM))
• Brise Pharmaceuticals Co., Ltd.: Phase 3 study started recruiting, 2079 planned (Migraine, With or Without Aura)
• Britannia Pharmaceuticals Ltd.: Observational study closed enrollment, 312 enrolled (Advanced Parkinson Disease)
• Bucharest Emergency Hospital: Not applicable (device, behavioral) study in Colorectal (Colon or Rectal) Cancer, STOMACH NEOPLASM (320 participants)
• Bursa City Hospital: Observational study in Difficult Tracheal Intubation, Difficult Laryngoscopy (812 participants)
• Bursa Yuksek Ihtisas Training and Research Hospital: Observational study in Acute Appendicitis (400 participants)
• BYHEALTH Co., LTD: Not applicable (device, behavioral) study in Healthy Infants (370 participants)
• Cairo University: Observational study in Diabetes (DM) (323 participants)
• Cairo University: Observational study in Periodontal Diseases, Dental Caries (369 participants)
• Can Tho University of Medicine and Pharmacy: Not applicable (device, behavioral) study in Soil-transmitted Helminth Infections (704 participants)
• Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Observational study in Esophageal Squamous Cell Carcinoma (500 participants)
• Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Observational study in Esophageal Squamous Cell Carcinoma (500 participants)
• Capital Medical University: Not applicable (device, behavioral) study closed enrollment, 438 enrolled (Ischemic Stroke, Atrial Fibrillation)
• Capital Medical University: Not applicable (device, behavioral) study in Respiratory Viral Infections, Influenza (618 participants)
• Capital Medical University: Phase 3 study closed enrollment, 692 enrolled (Acute Ischemic Stroke)
• Capital Medical University: Phase 3 study in Influenza, Human (570 participants)
• Cardenal Herrera University: Not applicable (device, behavioral) study completed, 400 enrolled (Fear of Childbirth)
• Cardiovascular Advancement and Research Excellence Institute: Not applicable (device, behavioral) study in Cardiovascular Diseases, Cardiovascular Risk Factor (6588 participants)
• Celltrion: Phase 3 study closed enrollment, 473 enrolled (Refractory or Relapsed Multiple Myeloma)
• Center for Reproductive Medicine Bocian: Observational study in Infertility, Donor Oocyte Assisted Reproduction (3000 participants)
• Central Hospital, Nancy, France: Observational study completed, 1000 enrolled (Endocrine Procedural Complications, Thyroid)
• Central Hospital, Nancy, France: Observational study in Lyme Borreliosis, Fibromyalgia (501 participants)
• Central South University: Observational study in Carbapenem-Resistant Acinetobacter Baumannii Infection (1000 participants)
• Centre Antoine Lacassagne: Not applicable (device, behavioral) study in Breast Cancer (1222 participants)
• Centre for Infectious Disease Research in Zambia: Not applicable (device, behavioral) study in Hepatitis B, HIV (460 participants)
• Centre for Infectious Disease Research in Zambia: Observational study closed enrollment, 374 enrolled (Tuberculosis)
• Centre Hospitalier Annecy Genevois: Observational study started recruiting, 410 planned (Thrombocytopenia, Platelet Transfusion)
• Centre Hospitalier Universitaire de Besancon: Not applicable (device, behavioral) study in Pregnant Women (628 participants)
• Centre Hospitalier Universitaire de la Réunion: Not applicable (device, behavioral) study in Rheumatic Heart Diseases, Scabies (900 participants)
• Centre Hospitalier Universitaire de Nice: Observational study in Craniofacial Fibrous Dysplasia (500 participants)
• Centre Hospitalier Universitaire de Nīmes: Observational study closed enrollment, 9600 enrolled (Medical Imaging)
• Centre Hospitalier Universitaire de Nīmes: Observational study in Non-scheduled Care (3000 participants)
• Centre Hospitalier Universitaire Vaudois: Not applicable (device, behavioral) study in Rheumatic Disorder, Rheumatoid Arthritis (RA) (320 participants)
• Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal: Observational study closed enrollment, 1741 enrolled (Motoric Cognitive Risk Syndrome, Aging Disorder)
• Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno: Observational study in Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection (814 participants)
• Centro per la Lotta Contro l'Infarto - Fondazione Onlus: Not applicable (device, behavioral) study closed enrollment, 1425 enrolled (Coronary Artery Disease, Coronary Disease)
• České Budějovice Hospital: Not applicable (device, behavioral) study completed, 518 enrolled (Persistent Atrial Fibrillation, Pulsed-field Ablation)
• Changchun BCHT Biotechnology Co.: Phase 2 study in Pertussis (Whooping Cough), Diphtheria (420 participants)
• Changzhou No.2 People's Hospital: Observational study in Cholecystolithiasis (5000 participants)
• Charite University, Berlin, Germany: Not applicable (device, behavioral) study started recruiting, 338 planned (Adjacent Segment Disease, Lumbar Spinal Stenosis)
• Chengdu Jinjiang Maternity and Child Health Hospital: Observational study in Intrapartum Fever (6144 participants)
• Chiesi Farmaceutici S.p.A.: Phase 3 study in Asthma (700 participants)
• Children's Hospital of Fudan University: Observational study in Neonatal Congenital Heart Disease (6300 participants)
• China Institute of Sport Science: Observational study in Physical Fitness, Aging (8960 participants)
• China Medical University Hospital: Observational study completed, 73404 enrolled (Herpes Zoster, Dementia)
• China National Center for Cardiovascular Diseases: Not applicable (device, behavioral) study in Cardiovascular Diseases (600 participants)
• China National Center for Cardiovascular Diseases: Not applicable (device, behavioral) study in Chronic Coronary Syndrome (400 participants)
• China National Center for Cardiovascular Diseases: Not applicable (device, behavioral) study in Paroxysmal Atrial Fibrillation (390 participants)
• China National Center for Cardiovascular Diseases: Not applicable (device, behavioral) study in Ventricular Tachycardia (VT), Ischemic Cardiomyopathy (526 participants)
• China National Center for Cardiovascular Diseases: Observational study in Coronary Artery Disease, Coronary Artery Bypass Grafting (2290 participants)
• Chinese Academy of Medical Sciences, Fuwai Hospital: Observational study in Cardiomyopathies, Heart Failure (1000 participants)
• Chinese University of Hong Kong: Not applicable (device, behavioral) study in Bladder Cancer (440 participants)
• Chinese University of Hong Kong: Not applicable (device, behavioral) study in Psychological Well-being, Gratitude (360 participants)
• Chinese University of Hong Kong: Not applicable (device, behavioral) study started recruiting, 732 planned (Bladder Cancer)
• Chongqing Center for Disease Control and Prevention: Not applicable (device, behavioral) study in Fall, Fall Accident (320 participants)
• Chulalongkorn University: Not applicable (device, behavioral) study in Ecchymosis, Adverse Anesthesia Outcome (450 participants)
• Chulalongkorn University: Observational study completed, 1000 enrolled (Critical Illness)
• Chulalongkorn University: Phase 4 study in Leptospirosis, Chemoprophylaxis (1000 participants)
• City University of Hong Kong: Not applicable (device, behavioral) study in Fertility Awareness, Ovarian Reserve (600 participants)
• CMR Surgical Ltd: Observational study started recruiting, 1200 planned (Robotic-assisted Soft-tissue Surgery)
• College of Physicians and Surgeons Pakistan: Not applicable (device, behavioral) study in Symptomatic Apical Periodontitis (662 participants)
• Copenhagen Trial Unit, Center for Clinical Intervention Research: Not applicable (device, behavioral) study in Coronary Revascularization, Coronary Artery Disease (15000 participants)
• Copenhagen University Hospital, Rigshospitalet: Not applicable (device, behavioral) study started recruiting, 1986 planned (Aortic Valve Stenosis)
• Corona Management Systems: Not applicable (device, behavioral) study completed, 115589 enrolled (Incentives)
• CSPC Megalith Biopharmaceutical Co.,Ltd.: Phase 2 study in Herpes Zoster (496 participants)
• CSPC Megalith Biopharmaceutical Co.,Ltd.: Phase 3 study in Triple Negative Breast Cancer (550 participants)
• CytomX Therapeutics: Phase 2 study in Colo-rectal Cancer (368 participants)
• Dacima Consulting: Observational study in Malnutrition, Sarcopenia (4000 participants)
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company: Observational study in Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer (400 participants)
• Danderyd Hospital: Observational study closed enrollment, 2420 enrolled (COVID 19, Respiratory Synctial Virus)
• Daping Hospital and the Research Institute of Surgery of the Third Military Medical University: Observational study in Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms (717 participants)
• Dartmouth-Hitchcock Medical Center: Not applicable (device, behavioral) study in Weight Bias (610 participants)
• DejthidaNathaphong: Observational study completed, 246587 enrolled (Valid MeSH Conditions, Hypertension (HTN))
• Delta University for Science and Technology: Not applicable (device, behavioral) study completed, 427 enrolled (Normal Labor)
• Dr. Ram Manohar Lohia Hospital: Observational study completed, 600 enrolled (Non-invasive Ventilation, Intensive Care (ICU))
• Duke University: Phase 4 study closed enrollment, 2174 enrolled (Malaria,Falciparum, Malaria in Pregnancy)
• ECOG-ACRIN Cancer Research Group: Not applicable (device, behavioral) study in Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm (448 participants)
• Ecole Polytechnique Fédérale de Lausanne: Observational study in Acute Conditions (3000 participants)
• Elsan: Phase 3 study in Atrial Fibrillation (AF) (636 participants)
• Epicentre: Phase 4 study in Ebola, Bundibugyo Virus Disease (BVD) (20000 participants)
• Erasme University Hospital: Phase 4 study started recruiting, 2000 planned (Any Patient Under General Anesthesia With Propofol Induction)
• Erasmus Medical Center: Not applicable (device, behavioral) study in Aortic Valve Stenosis and/or Insufficiency, Hypoattenuated Leaflet Thickening (422 participants)
• Erasmus Medical Center: Observational study in Trauma Associated Hemorrhage (750 participants)
• Eye & ENT Hospital of Fudan University: Observational study in Tinnitus (225792 participants)
• First Affiliated Hospital of Wannan Medical College: Phase 3 study in Ischemia Stroke, TIA (Transient Ischemic Attack) (520 participants)
• First Affiliated Hospital of Zhejiang University: Observational study in Vitamin D Deficiency (10000 participants)
• First Affiliated Hospital, Sun Yat-Sen University: Observational study in Inflammatory Bowel Diseases (IBD), Crohn Disease (2000 participants)
• First Affiliated Hospital, Sun Yat-Sen University: Observational study in Ulcerative Colitis (Disorder) (1000 participants)
• First People's Hospital of Hangzhou: Observational study in Multimodal Ultrasound Data Collection (30000 participants)
• First People's Hospital of Hangzhou: Observational study in Peutz-Jeghers Syndrome (1000 participants)
• Fondation FondaMental: Not applicable (device, behavioral) study in Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP) (3000 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Not applicable (device, behavioral) study in Acute Myeloid Leukemia (420 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Not applicable (device, behavioral) study in Breast Cancer (496 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Not applicable (device, behavioral) study in Carotid Artery, Carotid Arteriosclerosis (420 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Not applicable (device, behavioral) study in Lysosomal Storage Diseases (1000 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Observational study in Aortic Aneurysm and Dissection, Thoracic Endovascular Aortic Repair (385 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Observational study in Infertility Assisted Reproductive Technology, Ovarian Aging (400 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Observational study in Myelofibrosis (MF), Polycythemia Vera (1190 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Observational study in Nephrocalcinosis (800 participants)
• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: Observational study in Breast Neoplasms (200075 participants)
• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: Observational study in Cardiometabolic Health Indicators, Child Health (2000 participants)
• Foundation University Islamabad: Observational study in SLE - Systemic Lupus Erythematosus (3000 participants)
• French Cardiology Society: Observational study in Cardiogenic Shock (1000 participants)
• FrieslandCampina: Phase 3 study in Infant ALL (387 participants)
• Fudan University: Not applicable (device, behavioral) study in Breast Cancer, Neoadjuvant Therapy (1024 participants)
• Fudan University: Not applicable (device, behavioral) study in Influenza Vaccination (1300 participants)
• Fudan University: Not applicable (device, behavioral) study in Influenza Vaccination (3060 participants)
• Fudan University: Not applicable (device, behavioral) study in RSV Immunization (1500 participants)
• Fudan University: Observational study in Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) (20000 participants)
• Fudan University: Observational study in Vaccination (2000 participants)
• Fudan University: Phase 2 study in Breast Cancer, TNBC - Triple-Negative Breast Cancer (572 participants)
• Fudan University: Phase 2 study in HER2-positive Breast Cancer, Early Breast Cancer (EBC) (358 participants)
• Fudan University: Phase 3 study in Locally Advanced Colon Cancer, pMMR (480 participants)
• Fujian Medical University Union Hospital: Observational study in Acute Ischemic Stroke (2000 participants)

Browse ClinicalTrialStartPulse by category and location · Search and filter ClinicalTrialStartPulse